Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06746402 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
42
Enrollment target
2
Study locations

NCT06746402 is a Phase 1 study of Healthy Volunteers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 42 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06746402, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
42 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG BMS-986278

Study Locations (2)

Texas

  • ICON San Antonio - San Antonio

Utah

  • Local Institution - 0001 - Salt Lake City

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2025-02-10
Est. Completion 2025-09-11
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT06746402

The ClinicalTrials.gov registry entry for NCT06746402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (91% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06746402 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT06746402 about?

NCT06746402 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants". The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

What is the current status of trial NCT06746402?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-02-10. Estimated completion is 2025-09-11.

What conditions does trial NCT06746402 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT06746402?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BMS-986278 (DRUG).

Who is sponsoring clinical trial NCT06746402?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06746402 being conducted?

This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.